Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: A Phase III study

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 879-884

  Dimitroulis, John ^a   Rapti, Angeliki ^a   Stathopoulos, George P ^b   Rigatos, Sotiris ^b   Stathopoulos, John ^b   Koutantos, John ^b   Athanasiadis, Athanasios ^c   Tsikritsaki, Kyriaki ^a   Karaindros, Dimitris ^d   Katis, Kostas ^d   Antoniou, Dimosthenis ^a   Toumbis, Michalis ^a   Giamboudakis, Pantelis ^a  

^a Hospital of Thoracic Diseases   (Greece)

^b Errikos Dunant Hospital   (Greece)

^c GENERAL HOSPITAL OF LARISSA   (Greece)

^d THRIASIO GENERAL HOSPITAL   (Greece)

Author keywords

Cisplatin; Paclitaxel; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SMALL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT COMPLIANCE;

EID: 55249108244     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000086     Document Type: Article

References (21)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics 2004. CA Cancer J Clin 54: 8-15, 2004.
2. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PWM, Reznek R, Masud T, Gregory W and Wrigley PFM: A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12: 1427-1435, 1994.
3. Moore TD and Korn EL: Phase II trial design considerations for small-cell lung cancer. J Natl Cancer Inst 84: 150-158, 1992.
4. Loehrer PJ, Einhorn LH and Greco FA: Cisplatin plus etoposide in small-cell lung cancer. Semin Oncol 15: 2-8, 1988.
5. Giaccone G, Ferrati P, Donadio M, et al: Reinduction chemotherapy in small-cell lung cancer. Eur J Cancer Clin Oncol 23: 1697-1703, 1987.
6. Jett JR, Everson L, Therneau TM, et al: Treatment of limited stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J Clin Oncol 8: 33-39, 1990.
7. Ettinger DS, Finkelstein DM, Ritch PS, et al: Study of either ifosfamide or teniposide compared to a standard chemotherapy of extensive disease small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588). Lung Cancer 37: 311-317, 2002.
8. Lowenbraun S, Birch R, Buchanan R, et al: Combination chemotherapy in small cell lung carcinoma: a randomized study of two intensive regimens. Cancer 54: 2344-2350, 1984.
9. Johnson DH, Einhorn LH, Birch R, et al: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5: 1731-1738, 1987.
10. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Ornura GA and Greco AF: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10: 282-291, 1992.
11. Sundstrom S, Bremnes RM, Kaasa S, Assebo U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlud E, Hannisdal E and Aamdal S for the Norwegian Lung Cancer Study Group: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer. Results from a randomized Phase III trial with 5 years' follow up. J Clin Oncol 20: 4665-4672, 2002.
12. Einhorn LH, Crawford J, Birch R, et al: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol 6: 451-456, 1988.
13. Fukuoka M, Furuse K, Saijo N, et al: Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83: 855-861, 1991.
14. Mavroudis D, Papadakis E, Veslemes V, et al: A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first line treatment in patients with small-cell lung cancer. Ann Oncol 12: 463-470, 2001.
15. Therasse P, Arbuck SG, Eisenhower EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000.
16. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Group Study. J Clin Oncol 13: 1430-1435, 1995.
17. Kirschling RJ, Grill JP, Marks RS, et al: Paclitaxel and G-CSF in previously untreated patients with extensive stage small cell lung cancer: a phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 22: 517-522, 1999.
18. Bunn PA and Kelly K: A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer. Semin Oncol 24 (Suppl. 12): 144-148, 1997.
19. Loehrer PJ, Rynard S, Ansari R, et al: Etoposide, ifosfamide and cisplatin in extensive small-cell lung cancer. Cancer 69: 669-673, 1992.
20. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Ann Oncol 5: 601-607, 1994.
21. Loehrer PJ, Ansari R, Gonin R, et al: Cisplatin plus etoposide with or without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group Study. J Clin Oncol 13: 2594-2599, 1995.